To elucidate the acute metabolic actions of insulin-like growth factor I (IGF-I), we administered a primed (250 ,ug/kg), continuous (5 gg/kg. min) infusion of human recombinant (Thr 59) IGF-I or saline to awake, chronically catheterized 24-h fasted rats for 90 min. IGF-I was also infused while maintaining euglycemia (glucose clamp technique) and its effects were compared to those of insulin. IGF-I infusion caused a twofold rise in IGF-I levels and a 75-85% decrease in plasma insulin. When IGF-I alone was given, plasma glucose fell by 30-40 mg/dl (P < 0.005) due to a transient twofold increase (P < 0.05) in glucose uptake; hepatic glucose production and plasma FFA levels remained unchanged. IGF-I infusion with maintenance of euglycemia produced a sustained rise in glucose uptake and a marked stimulation of 13-3Hjglucose incorporation into tissue glycogen, but still failed to suppress glucose production and FFA levels. IGF-I also produced a generalized 30-40% reduction in plasma amino acids, regardless of whether or not hypoglycemia was prevented. This was associated with a decrease in leucine flux and a decline in the incorporation of i1-'4Clleucine into muscle and liver protein (P < 0.05). When insulin was infused in a dosage that mimicked the rise in glucose uptake seen with IGF-I, nearly identical changes in amino acid metabolism occurred. However, insulin suppressed glucose production by 65% and FFA levels by 40% (P < 0.001). Furthermore, insulin was less effective than IGF-I in promoting glycogen synthesis.
Introduction
Insulin-like growth factor I (IGF-I),' the putative mediator of growth hormone's somatotrophic actions in vivo (1) Receivedfor publication 27 June 1988 and in revisedform 1I November 1988. 1. Abbreviations used in this paper: IGF-I, insulin-like growth factor I; KIC, a-ketoisocaproate. been recognized to exert metabolic actions in vitro that closely resemble those of insulin. For example, IGF-I can mimic insulin's capacity to promote glucose uptake and metabolism in isolated muscle and adipose tissue (2) (3) (4) (5) , stimulate glycogen synthesis in rat heart and diaphragm muscle (2, 5) , accelerate amino acid transport in fibroblasts (6) , and increase net protein synthesis in cartilage (7) . IGF-I's metabolic effects in vitro occur at much lower concentrations in muscle than in adipose tissue (3) (4) (5) (6) ; IGF-I appears to act through its own receptor in muscle, but only through its capacity to bind to the insulin receptor of adipocytes (8-1 1) .
The limited availability of IGF-I in purified form has, until recently, prevented a systematic examination of IGF-I's effects on body fuel metabolism under in vivo conditions. Using partially purified preparations of IGF-I, early studies demonstrated a plasma glucose lowering effect that was particularly evident in hypophysectomized and adrenalectomized animals (12, 13). More recently, Froesch and his colleagues have demonstrated that intravenous injection of IGF-I purified from human serum or synthesized by recombinant DNA techniques reduced blood glucose and stimulated glycogen synthesis in normal or hypophysectomized rats given serum containing anti-insulin antibodies (14) . Recombinant human IGF-I has also been demonstrated to produce a rapid hypoglycemic effect in healthy human subjects, much like insulin (15) . These studies, however, have not elucidated the mechanisms underlying IGF-I's glucose lowering action; namely, whether IGF-I, like insulin, lowers blood glucose levels by both decreasing hepatic glucose production and increasing glucose uptake (16) .
The chronic growth promoting effects of crude preparations of IGF-I in rats (17) have recently been reproduced with chronic infusions of recombinant human IGF-I in both hypophysectomized and insulin-deficient diabetic rats (18, 19) . These findings imply that IGF-I may exert protein anabolic effects, a view supported by IGF-I's stimulatory effect on protein metabolism in vitro (7) . However, it is unclear whether such effects (a) require chronic hormone administration or (b) would occur in mature animals that are neither growth hormone nor insulin-deficient.
The present study was undertaken to examine the acute effects of recombinant human IGF-I upon glucose and amino acid metabolism in awake, 24- (-20 Il/min) of saline with dilute heparin (1-2 U/ml).
Procedures. Each animal received a primed (9 uCi) continuous (0.14 ,Ci/min) infusion of both [3-3H] glucose and L-[ I-'4C]leucine for 180 min. After a 90-min tracer equilibration period, animals were assigned to one of four experimental protocols. Group 1 (n = 5) received only normal saline and served as the control group. Group 2 (n = 5) received recombinant human (Thr 59) IGF-I (20) administered as a 250-pg/kg bolus followed by a 5-pg/kg. min continuous infusion for 90 min. Group 3 (n = 6) was given an identical primed-continuous IGF-I infusion; however, plasma glucose was maintained at baseline concentrations throughout using a variable rate infusion of 20% dextrose that was adjusted at 5-min intervals (21) . The fourth group (n = 6) received a primed-continuous infusion of regular porcine insulin for a total of 90 min. The priming dose was given over the initial 10 min of the experiment at twice the continuous infusion rate. The continuous infusion rate was 1.4 mU/min -kg. Throughout, plasma glucose was maintained at baseline levels using the same glucose clamp procedure (21) 4 ml and the total volume infused over this time was 6-7 ml. At the end of the 180-min infusion period, the rats were killed by intravenous pentobarbital, the abdomen and chest were rapidly opened, and -1 g pieces of liver, rectus muscle, and heart were excised. The tissues were rapidly freeze-clamped and stored at -70°C for later analysis.
Analytical methods. Plasma glucose was measured using a glucose analyzer (Yellow Springs Instrument Co., Yellow Springs, OH), and [3-3H] glucose radioactivity was determined by a modification of the Somogyi precipitation procedure, as previously described (22) . Plasma concentrations of acidic and neutral amino acids were measured by cation-exchange chromatography using an automated amino acid analyzer (Dionex D-500, Dionex Corp., Sunnyvale, CA). [1-'4C]leucine was separated from bicarbonate and a-ketoisocaproate (KIC) using Dowex 50W cation exchange resin (Dow Corning Corp., Midland, MI). Plasma free fatty acid concentrations were assayed using a modification of the Dole extraction procedure (23) . Plasma lactate determinations were made using a lactate analyzer (Yellow Springs Instrument Co., Inc.). Plasma insulin levels were determined with a double antibody radioimmunoassay method (24) ; rat insulin standards were used except for samples obtained during infusions of exogenous porcine insulin which were analyzed with a porcine insulin standard. Samples for total plasma IGF-I (bound and free) were acid ethanol extracted and measured by a double antibody radioimmunoassay (25) Glycogen was extracted and purified from carefully weighed frozen samples of heart, liver and skeletal muscle as described by Waalas and Waalas (26) . Extracted glycogen was subsequently hydrolyzed to glucose (27) and then measured by the glucose oxidase method. Radioactivity present in the purified glycogen was measured in a liquid scintillation system; quenching was corrected for with an external standard. Protein was purified from additional pieces of the frozen heart, liver and skeletal muscle tissues, as described by Morgan et al. (28) . 1-'4C radioactivity was assayed from 10-mg samples of purified tissue protein to determine the incorporation of labeled leucine radioactivity into protein.
Calculations. The basal fluxes of glucose and leucine were calculated by dividing the tracer infusion rate by the mean ofthree measurements of substrate specific activity obtained during the last 30 min of the equilibration period. During the experimental infusion period, the rates of endogenous glucose production and total body glucose uptake were estimated using a two-compartment model of glucose kinetics, described elsewhere (29) . In those studies in which the glucose clamp technique was utilized, the rate of endogenous glucose production was calculated by subtracting the rate ofexogenous glucose infusion during the last 30 min of the study from the rate of glucose production determined from the tracer data. For leucine, since no accepted nonsteady-state model exists, flux was estimated only in the basal period and during the last 30 min of the experimental infusion period when plasma leucine specific activity approached a new steady state (coefficient of variation < 10% over the sampling period). At steady state the flux of leucine into and out of plasma reflects protein breakdown and the sum of oxidative and protein synthetic processes, respectively.
Since leucine oxidation ('4C02 production) was not measured in the current study, leucine flux rates could not be used to estimate protein synthesis; this was instead evaluated by determining the incorporation of ['4C]leucine into tissue proteins (see below). In estimating leucine flux into plasma we used the specific activity of plasma leucine rather than a-ketoisocaproate (KIC) to keep blood losses within acceptable limits. As a result, leucine flux rates calculated from plasma leucine specific activity probably led to a small underestimation of rates of protein breakdown. Nevertheless, recent data suggest that the response of leucine flux to insulin infusion is qualitatively similar whether leucine or KIC specific activity is used (30) . Leucine specific activity was also used (see below) to estimate the rate of tracer incorporation into tissue protein (an index of protein synthesis), as it is unclear whether plasma leucine or KIC specific activity more closely reflects the actual precursor pool for tissue protein synthesis (31) .
Incorporation of 3H and 14C (derived from circulating glucose and leucine, respectively) during the study period was measured in tissue samples in all animals. The flux of these substrates from plasma into tissues during the experimental period was estimated by dividing the total disintegrations per minute in the purified tissue glycogen or protein samples by the mean plasma specific activity of the substrate during the experimental period.
All data are expressed as mean±SE. Data were analyzed using analysis of variance (ANOVA) (corrected for repeated measures when applicable). In addition, a two-tailed Student's t test was done to localize time-points at which significant differences occurred.
Results
Effect ofIGF-I and insulin on glucose metabolism. Infusion of IGF-I alone produced a nearly twofold increase above baseline (P < 0.05) in plasma IGF-I concentration (Fig. 1) , whereas plasma insulin levels significantly declined (Table I) . As shown in Fig. 1 at baseline (coefficient of variation < 5%), plasma IGF-I increased by 120% and insulin concentration again declined (Table I) . As shown in Fig. 2 , glucose uptake increased twofold, an effect that persisted throughout the entire 90-min infusion period. In contrast, hepatic glucose production (4.8±0.4 mg/kg min, basal) was not significantly affected (4.4±0.7 mg/kg. min at 60-90 min), even though hypoglycemia was prevented. Table II shows the effect of IGF-I on the incorporation of [3-3H] glucose into tissue glycogen. IGF-I produced a marked stimulation of net glycogen synthesis in skeletal muscle, heart, and liver (P < 0.05 vs. saline infusion).
Infusion of insulin produced a ninefold increase in circulating insulin levels, but no significant change in IGF-I concentration (Table I ). Plasma glucose concentration was maintained at baseline values that were not significantly different from those achieved during the IGF-I clamp study. As shown in Fig. 2 , glucose uptake increased twofold; a response indistinguishable from that observed during infusion of IGF-I. However, insulin markedly suppressed hepatic glucose production (from 4.1±0.2 to 1.4±2 mg/kg-min, P < 0.001) in distinct contrast to IGF-I. On the other hand, insulin was significantly less effective than IGF-I in stimulating incorporation of labeled glucose into liver and heart tissue glycogen (P < 0.05); insulin failed to increase net glycogen synthesis in liver, heart or skeletal muscle over saline control values (Table II).
Plasma FFA concentrations before and at the end of the IGF-I and insulin infusions are shown in Table I . Infusion of IGF-I had no significant effect on plasma FFA concentrations as compared with either basal or saline control values, regardless of whether or not hypoglycemia was prevented. In contrast, insulin infusion suppressed circulating FFA levels by 40% (P < 0.001). Plasma lactate rose similarly when IGF-I and insulin were administered under euglycemic conditions, but was unchanged during the saline control study (Table I) .
Effect of IGF-I and insulin on amino acid metabolism. IGF-I infusion produced a 30-40% reduction in total amino acid concentration that was similar whether or not euglycemia was maintained (Table I ). This effect extended to virtually all amino acids measured (Table III) and did not occur during the saline control study. The response to IGF-I was rapid and appeared to be near-maximal after 60 min, as illustrated by plasma leucine which declined to levels 35-45% below baseline between 60 and 90 min (P < 0.01) (Fig. 3) . The concentration of [1-'4C]leucine was not, however, significantly af- fected during either ofthe two IGF-I protocols when compared to the saline control study. As a result, leucine specific activity rose more sharply during both IGF-I studies than during infusion of saline (P < 0.05) (Fig. 3) . Table IV demonstrates the effects of IGF-I on estimated rates of leucine flux. Infusion of IGF-I produced a twofold greater decline in leucine flux than was observed during saline infusion. The suppressive effect of IGF-I on leucine flux was not significantly different regardless of whether or not euglycemia was maintained. In keeping with these findings, the rate of incorporation of labeled leucine into tissue protein not only failed to increase, it actually decreased significantly during IGF-I infusion as compared to saline control values (Table V) .
Infusion of insulin produced a similar, albeit slightly less pronounced decline in circulating amino acids as compared to Values represent the incorporation of labeled glucose from plasma into tissue glycogen during the 3 h infusion of tracer. Data are presented as mean±SE. * P < 0.05 as compared to the saline control study.
IGF-I, except for the absence of any reduction in circulating alanine (Table I and III) . Insulin also induced changes in plasma leucine and leucine specific activity that were not significantly different from those seen with IGF-I Leucine flux declined significantly compared with saline infusion, a change that was indistinguishable from that observed during infusion of IGF-I (Table IV) . Moreover, insulin (like IGF-I) led to a decline in the incorporation of labeled leucine into tissue protein (Table V) .
Discussion
The current observations define the acute in vivo effects of recombinant IGF-I on glucose kinetics and on plasma amino acid metabolism. In addition, they provide the opportunity to compare the actions of IGF-I with those of insulin when given in doses that produce an equivalent stimulation of glucose metabolism. Our data demonstrate that IGF-I has potent stimulatory effects on glucose disposal, causes generalized hypoaminoacidemia, and inhibits the rate of leucine appearance into plasma. These insulin-like effects must be attributed to IGF-I per se, since circulating insulin levels declined during IGF-I infusion.
Although the effects of IGF-I in some cases were indistinguishable from insulin, there were a number of instances where substantial differences were evident. Considering first glucose disposal, both IGF-I and insulin at the doses used provoked comparable, sustained increases in glucose uptake in the fasted rat when euglycemia was maintained. This effect of IGF-I was transient when glucose was allowed to fall, presumably due to the fall in glucose concentration itself and the concomitant release of counterregulatory hormones (32) . It is noteworthy that, on a molar basis, the dose ofinsulin was only 1-2% ofthat for IGF-I. This is in keeping with previous reports indicating that insulin is a more potent hypoglycemic agent than IGF-I in vivo (13, 15, 33) .
Previous studies have demonstrated that the principal site of enhanced glucose uptake during euglycemic hyperinsulinemia is muscle tissue (34) . This may also be the case for IGF-I. IGF-I infusion markedly increased glycogen synthesis in heart and skeletal muscle, a finding consistent with earlier reports by Froesch and co-workers showing IGF-I to be a potent stimulator ofglucose uptake (4) and glycogen synthesis ( 14) in skeletal muscle. The liver also demonstrated an increase in glycogen synthesis with IGF-I infusion, implying that tissues other than muscle may have participated in IGF-I's enhancement of glucose disposal. Interestingly, although increases in glucose disposal were essentially identical with IGF-I or insulin, only IGF-I significantly increased glucose incorporation into tissue glycogen (Table II) . Although we have no definitive explanation for this difference, it may be related to the fact that only insulin suppressed circulating FFA, the primary respiratory fuel for both heart and skeletal muscle. By reducing the availability of FFA, insulin may have directed glucose metabolism toward oxidation (35) , thereby diminishing the rate of glycogen formation as -compared with IGF-I. Such differences in tissue glucose handling might not be evident at higher rates of insulin infusion that increase tissue glucose utilization to a greater extent, since under these conditions insulin clearly promotes glucose storage as glycogen (36) .
Although IGF-I and insulin had similar effects on glucose uptake, their action on hepatic glucose production was strik- duction to IGF-I and insulin remains uncertain, this finding does not appear to be attributable to differences in the availability of either glycogenic amino acids (Table III) or lactate (Table I) . Perhaps a relative deficiency of hepatic IGF-I receptors (37) or the stimulatory effects of FFA on hepatic gluconeogenesis (38) contribute to the diminished suppression of glucose production during IGF-I infusion. It may at first glance appear paradoxical that IGF-I did not affect gluconeogenesis, but still enhanced glycogen synthesis in liver. This could be explained if gluconeogenesis were less sensitive to inhibition by IGF-I than is glycogenolysis. Such a differential effect exists for insulin in man and the dog (39, 40) . Our inability to demonstrate a reduction in circulating FFA levels during IGF-I infusion constitutes an additional feature that distinguishes the actions of IGF-I from those of (8, 9, 11, 41) . In contrast to glucose production and FFA concentration, IGF-I's effects on plasma amino acids, leucine kinetics, and leucine incorporation into protein closely resemble those seen with insulin. IGF-I, like insulin, caused generalized hypoaminoacidemia and accelerated the rise in plasma leucine specific activity compared with saline, presumably as a result of an inhibition of tissue protein degradation. The slow rise in plasma leucine specific activity in the saline-infused rats is likely due to conservation of body protein during more prolonged fasting, recycling of label, or both (42) . Since plasma leucine appeared to be near steady state at the end of the equilibration period and over the last 30 min of the experimental period, we used the steady-state assumption to estimate the leucine flux. Regardless of the potential quantitative errors introduced by this approach, it is clear that at least from a qualitative standpoint, leucine flux fell to a significantly greater extent in both the IGF-I and the insulin infused rats when compared to control animals. A decrease in leucine flux has also been reported during euglycemic hyperinsulinemia in the dog and man (43, 44) . The observed decline in labeled leucine incorporation into heart, skeletal muscle, and liver protein together with the fall in total leucine flux suggests that the amino acid lowering effect of both insulin and IGF-I results from a diminution of the rate of protein degradation rather than an increase in protein synthesis in the fasted rat.
The extent to which our results represent a physiologic effect of IGF-I is difficult to resolve. Although we observed only a twofold rise in IGF-I concentration, a greater increment in the free concentration presumably occurred. Nevertheless, the changes in total IGF-I immunoreactivity produced during this study are similar to those reported in humans after injection of growth hormone (45) . A second closely related issue is whether the effects of IGF-I on glucose uptake and amino acid metabolism are due to IGF-I acting through its own specific receptor or whether they are attributable to binding to the insulin receptor. The latter explanation is less likely considering the apparent lack of effect of IGF-I on glucose production and fatty acid mobilization, processes more sensitive to insulin than glucose uptake (16, 46 
